NOV 17, 202651 MINS READ
Isopropyl palmitate (hexadecanoic acid, 1-methylethyl ester; CAS 142-91-6) is synthesized via esterification of palmitic acid (C16:0) with isopropyl alcohol, yielding a clear, colorless liquid with a molecular weight of 298.5 g/mol 1. Its hydrophilic-lipophilic balance (HLB) value of approximately 11.5 positions it as a semi-polar lipid, facilitating interfacial activity at oil-water boundaries 3. In SEDDS formulations, IPP functions simultaneously as a lipid carrier, viscosity modulator, and solubilization enhancer for lipophilic drugs 12. The ester exhibits a density of 0.850–0.855 g/cm³ at 25°C, a refractive index (nD²⁰) of 1.435–1.438, and negligible water solubility (<0.01 mg/mL), ensuring phase separation stability in aqueous environments prior to emulsification 11.
Key functional attributes include:
The ester's chemical stability under physiological pH (1.2–7.4) and resistance to enzymatic hydrolysis by gastric lipases further distinguish it from glyceride-based carriers, which undergo rapid lipolysis in the gastrointestinal tract 11. However, IPP's moderate polarity necessitates co-formulation with high-HLB surfactants (HLB 12–16) to achieve spontaneous emulsification, as discussed in subsequent sections 24.
Optimal SEDDS formulations balance lipid, surfactant, and co-surfactant ratios to achieve thermodynamic stability and rapid emulsification. Patent literature reveals that IPP is typically incorporated at 1–70 wt% of the total formulation, with most pharmaceutical applications employing 5–25 wt% to balance drug solubility and emulsion stability 24. A representative formulation comprises:
Case Study: Candesartan Cilexetil SEDDS
A formulation containing 8 wt% IPP, 45 wt% Polysorbate 80, 22 wt% ethanol, and 10 wt% candesartan cilexetil achieved a mean droplet diameter of 85 nm and demonstrated a 3.2-fold increase in oral bioavailability (AUC₀₋₂₄ₕ) compared to crystalline drug suspension in beagle dogs 5. The IPP component contributed to a drug solubility of 62 mg/mL, while the high surfactant content (HLB 14.2) enabled spontaneous emulsification within 90 seconds of gastric fluid contact 5.
Formulation Optimization Strategies:
The superior oral bioavailability conferred by IPP-based SEDDS arises from multiple synergistic mechanisms:
Upon contact with gastrointestinal fluids, SEDDS spontaneously form oil-in-water microemulsions with droplet diameters of 20–300 nm, increasing the effective surface area for drug dissolution by 10²–10³-fold relative to bulk powder 58. IPP's moderate polarity (dielectric constant ε ≈ 3.2) facilitates drug partitioning into the aqueous phase, with partition coefficients (log Pₒ/w) shifting from >5 (pure drug) to 2–3 (emulsified drug) 2. For butylphthalide SEDDS containing 10 wt% IPP, dissolution rates exceeded 85% within 15 minutes in simulated gastric fluid (pH 1.2), compared to <20% for conventional tablets 713.
Long-chain fatty acid esters like IPP promote intestinal lymphatic absorption via chylomicron incorporation, circumventing hepatic first-pass metabolism 1014. Studies with lipophilic model drugs (e.g., coenzyme Q10, sirolimus) demonstrate that SEDDS containing ≥10 wt% IPP achieve lymphatic transport fractions of 30–45%, versus <5% for aqueous suspensions 14. This mechanism is particularly advantageous for drugs with extensive hepatic metabolism (extraction ratio >0.7), such as lercanidipine HCl, where IPP-SEDDS increased absolute bioavailability from 12% to 38% in human pharmacokinetic trials 5.
Polyoxyethylene surfactants (Tween 80, Cremophor EL) reversibly modulate tight junction integrity and inhibit P-glycoprotein (P-gp) efflux pumps in enterocytes 12. In Caco-2 cell monolayers, SEDDS formulations with 40 wt% Tween 80 and 8 wt% IPP increased apparent permeability (Papp) of the P-gp substrate rhodamine 123 by 4.8-fold, with transepithelial electrical resistance (TEER) recovering to baseline within 2 hours post-exposure 12. Importantly, IPP itself exhibits minimal cytotoxicity (IC₅₀ > 500 μg/mL in MTT assays), ensuring safety at therapeutic concentrations 11.
Long-term stability of IPP-SEDDS requires control of phase separation, drug precipitation, and oxidative degradation. Accelerated stability studies (40°C/75% RH, 6 months) reveal:
Critical Quality Attributes (CQAs):
Candesartan cilexetil and eprosartan mesylate, BCS Class II drugs with aqueous solubilities <0.01 mg/mL, benefit significantly from IPP-SEDDS formulations 5. A clinical study (n=24 healthy volunteers) comparing a SEDDS capsule (8 wt% IPP, 10 mg candesartan) to a commercial tablet demonstrated:
Butylphthalide, a neuroprotective agent for ischemic stroke, exhibits erratic absorption (Fabs 15–40%) due to poor aqueous solubility (0.002 mg/mL) 7813. SEDDS formulations containing 1–65 wt% butylphthalide, 10–65 wt% non-ionic emulsifiers (Labrasol, Cremophor EL), and 5–15 wt% IPP achieve:
Sirolimus (rapamycin), a macrolide immunosuppressant with log P 4.3 and solubility 2.6 μg/mL, requires SEDDS to achieve therapeutic blood levels (10–20 ng/mL) 210. A formulation comprising 12 wt% IPP, 50 wt% Cremophor EL, 18 wt% PEG 400, and 5 wt% sirolimus demonstrated:
Vitamin E (α-tocopherol), coenzyme Q10 (ubiquinone), and curcumin exhibit bioavailabilities <10% when administered as powders 14. SEDDS containing 8–15 wt% IPP, 40–50 wt% Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate), and 3–8 wt% phosphatidylcholine achieve:
Recent patents describe IPP-free SEDDS for cannabinoids (THC, CBD) using high-PEG-content surfactants (≥30 wt% PEG moiety) 691516. However, formulations incorporating 5–10 wt% IPP as a secondary lipid phase demonstrate improved chemical stability of cannabinoids (ΔpH <0.3 after 6 months) and reduced capsule shell brittleness in soft gelatin formats 1516. Typical compositions include 10–20 wt% cannabinoid isolate, 40–50 wt% polysorbate-based surfactants, 10–15 wt% medium-chain triglycerides, and 5–10 wt% IPP 9.
Isopropyl palmitate is classified as Generally Recognized As Safe (GRAS) by the U.S. FDA
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| Tioga Research Inc. | Oral delivery of BCS Class II drugs with poor water solubility (log P > 3), including cardiovascular and immunosuppressant therapeutics requiring enhanced absorption and reduced first-pass metabolism. | SEDDS Formulation for Poorly Soluble Drugs | Isopropyl palmitate at 5-12 wt% enables drug solubility exceeding 50 mg/mL for lipophilic compounds, with spontaneous emulsification achieving 50-200 nm droplets within 2 minutes, enhancing oral bioavailability by 3-4 fold. |
| LEK Pharmaceuticals D.D. | Antihypertensive therapy requiring rapid onset of action and improved bioavailability for angiotensin receptor blockers in cardiovascular disease management. | Candesartan Cilexetil SEDDS | Formulation with 8 wt% isopropyl palmitate and Polysorbate 80 achieved 85 nm droplet size, 3.2-fold increase in oral bioavailability (AUC), and 62 mg/mL drug solubility with spontaneous emulsification within 90 seconds. |
| Shijiazhuang Pharma Group | Neuroprotective treatment for ischemic stroke patients requiring enhanced CNS drug absorption and reduced inter-subject pharmacokinetic variability in acute care settings. | Butylphthalide SEDDS Soft Capsules | SEDDS containing 1-65 wt% butylphthalide with non-ionic emulsifiers achieved 180-fold solubility enhancement to 0.36 mg/mL, >85% dissolution within 15 minutes, and absorption rate constant of 0.82 h⁻¹ versus 0.31 h⁻¹ for conventional formulations. |
| Amylin Pharmaceuticals Inc. | Immunosuppressive therapy post-transplantation requiring lymphatic transport to bypass hepatic first-pass metabolism and achieve sustained therapeutic drug levels. | Sirolimus SEDDS for Lymphatic Delivery | Formulation with 12 wt% isopropyl palmitate achieved 42% lymphatic uptake, 4.1-fold bioavailability improvement versus commercial solution, and <5% degradation after 24 months storage with antioxidant stabilization. |
| Avantsar Sdn Bhd | Dietary supplement delivery of fat-soluble vitamins, coenzyme Q10, and lipophilic antioxidants requiring enhanced oral bioavailability and stable formulation for consumer health products. | Lipophilic Nutraceutical SEDDS with Vitamin E TPGS | SEDDS combining 5-80 wt% oil carriers with phospholipids and Vitamin E TPGS achieved 3.5-fold increase in plasma Cmax for coenzyme Q10 (1.8 μg/mL vs 0.52 μg/mL) with stable micellar structure and linear dose proportionality across 50-200 mg range. |